Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

About Us

Featured News

Two M&A deals and $9B later, Lonnie Moulder is ramping up his latest biotech startup. And this one comes with global vision built in.

3/23/21 Lonnie Moulder may have been in silent running mode in the 2 years since he closed the $5 billion sale of TESARO to GlaxoSmithKline. But he hasn’t been idle.

Today during the China Healthcare Investment Conference in Shanghai, Moulder’s taking the wraps off a biotech startup he’s put together that has assembled a pipeline with 7 drugs in it, a plan to add several more therapies and a quick vault into the clinic for a company with a small but fast-expanding team that is growing roots in China and the US.

Continue reading

MiRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments

01/19/21 MiRagen Therapeutics, Inc. announced its name change to Viridian Therapeutics, Inc. (NASDAQ: VRDN). The Company also announced today the appointment of Jonathan Violin, Ph.D., M.B.A. as President and Chief Executive Officer and member of the Board of Directors.

Continue reading

Mission

  • To uncover and accelerate promising life science innovation
  • To enable talented entrepreneurs and innovators
  • To serve patients with unmet needs
Learn More

Investments

We make select early investments at the Seed stage in private biotech ventures as the lead or sole investor and participate in Series-A investments.

Company Formation

We launch and fund de novo companies to advance important innovations that may otherwise lack the proper resources to progress efficiently.

Approach & portfolio